Cargando…

1802. Evaluation of Clinical Pharmacists Use of a Blood Culture Follow-up Protocol Utilizing Rapid Molecular Diagnostic Testing

BACKGROUND: Studies have shown molecular rapid diagnostic testing (RDT) have been associated with improved clinical outcomes in bloodstream infections when combined with antimicrobial stewardship (AMS) intervention. Mercy Medical Center implemented the RDT Verigene® Blood-Culture Gram-Negative and G...

Descripción completa

Detalles Bibliográficos
Autores principales: Kerrigan, Alexandra, Percival, Kelly, Brock, Jeff
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6254690/
http://dx.doi.org/10.1093/ofid/ofy210.1458
_version_ 1783373781719318528
author Kerrigan, Alexandra
Percival, Kelly
Brock, Jeff
author_facet Kerrigan, Alexandra
Percival, Kelly
Brock, Jeff
author_sort Kerrigan, Alexandra
collection PubMed
description BACKGROUND: Studies have shown molecular rapid diagnostic testing (RDT) have been associated with improved clinical outcomes in bloodstream infections when combined with antimicrobial stewardship (AMS) intervention. Mercy Medical Center implemented the RDT Verigene® Blood-Culture Gram-Negative and Gram-Positive panels. After implementation, our prior study that evaluated time to optimal therapy after implementation of Verigene along with AMS intervention showed an improved time to optimal therapy (65 vs. 33 hours, P < 0.001). However, the process implemented was labor intensive for the AMS team to provide coverage 7 days per week. Therefore, we incorporated clinical pharmacists (CP) to provide coverage during evenings and weekends. METHODS: We performed a single-center, retrospective analysis of adult patients who were identified as having a positive blood culture from January 2016 to October 2017. The primary outcome was appropriateness of the CP recommendation based on RDT results compared with AMS recommendations. Secondary outcomes were time to RDT follow-up, and time to optimal antibiotic therapy. A survey of CP assessed workflow and confidence in performing this task. We evaluated each pharmacist’s recommendation based on RDT results, patient specific criteria, and antimicrobial reference tool. Suboptimal recommendations included: no de-escalation, no escalation to effective coverage, or lack of discontinuation. RESULTS: A total of 160 adult patients, 80 in each group were included. The AMS group provided optimal antibiotic therapy recommendations more often than CP (94% vs. 70%, P < 0.001). Time to follow-up by CP was significantly shorter compared with AMS (3.8 vs. 11; P < 0.001). The majority of the suboptimal recommendations were due to no de-escalation of antibiotic therapy. Time to optimal therapy was similar between groups (24.5 vs. 28; P = 0.920). A third of CP stated they are unlikely to recommend de-escalation to optimal therapy if patients were on effective therapy. CONCLUSION: CP can be utilized to expand coverage of RDT follow-up. The AMS team did provide significantly more optimal antimicrobial recommendations compared with CP. This study shows there is a need for continued education of CP on the importance of de-escalating patients to optimal antimicrobial therapy. DISCLOSURES: All authors: No reported disclosures.
format Online
Article
Text
id pubmed-6254690
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-62546902018-11-28 1802. Evaluation of Clinical Pharmacists Use of a Blood Culture Follow-up Protocol Utilizing Rapid Molecular Diagnostic Testing Kerrigan, Alexandra Percival, Kelly Brock, Jeff Open Forum Infect Dis Abstracts BACKGROUND: Studies have shown molecular rapid diagnostic testing (RDT) have been associated with improved clinical outcomes in bloodstream infections when combined with antimicrobial stewardship (AMS) intervention. Mercy Medical Center implemented the RDT Verigene® Blood-Culture Gram-Negative and Gram-Positive panels. After implementation, our prior study that evaluated time to optimal therapy after implementation of Verigene along with AMS intervention showed an improved time to optimal therapy (65 vs. 33 hours, P < 0.001). However, the process implemented was labor intensive for the AMS team to provide coverage 7 days per week. Therefore, we incorporated clinical pharmacists (CP) to provide coverage during evenings and weekends. METHODS: We performed a single-center, retrospective analysis of adult patients who were identified as having a positive blood culture from January 2016 to October 2017. The primary outcome was appropriateness of the CP recommendation based on RDT results compared with AMS recommendations. Secondary outcomes were time to RDT follow-up, and time to optimal antibiotic therapy. A survey of CP assessed workflow and confidence in performing this task. We evaluated each pharmacist’s recommendation based on RDT results, patient specific criteria, and antimicrobial reference tool. Suboptimal recommendations included: no de-escalation, no escalation to effective coverage, or lack of discontinuation. RESULTS: A total of 160 adult patients, 80 in each group were included. The AMS group provided optimal antibiotic therapy recommendations more often than CP (94% vs. 70%, P < 0.001). Time to follow-up by CP was significantly shorter compared with AMS (3.8 vs. 11; P < 0.001). The majority of the suboptimal recommendations were due to no de-escalation of antibiotic therapy. Time to optimal therapy was similar between groups (24.5 vs. 28; P = 0.920). A third of CP stated they are unlikely to recommend de-escalation to optimal therapy if patients were on effective therapy. CONCLUSION: CP can be utilized to expand coverage of RDT follow-up. The AMS team did provide significantly more optimal antimicrobial recommendations compared with CP. This study shows there is a need for continued education of CP on the importance of de-escalating patients to optimal antimicrobial therapy. DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2018-11-26 /pmc/articles/PMC6254690/ http://dx.doi.org/10.1093/ofid/ofy210.1458 Text en © The Author(s) 2018. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Kerrigan, Alexandra
Percival, Kelly
Brock, Jeff
1802. Evaluation of Clinical Pharmacists Use of a Blood Culture Follow-up Protocol Utilizing Rapid Molecular Diagnostic Testing
title 1802. Evaluation of Clinical Pharmacists Use of a Blood Culture Follow-up Protocol Utilizing Rapid Molecular Diagnostic Testing
title_full 1802. Evaluation of Clinical Pharmacists Use of a Blood Culture Follow-up Protocol Utilizing Rapid Molecular Diagnostic Testing
title_fullStr 1802. Evaluation of Clinical Pharmacists Use of a Blood Culture Follow-up Protocol Utilizing Rapid Molecular Diagnostic Testing
title_full_unstemmed 1802. Evaluation of Clinical Pharmacists Use of a Blood Culture Follow-up Protocol Utilizing Rapid Molecular Diagnostic Testing
title_short 1802. Evaluation of Clinical Pharmacists Use of a Blood Culture Follow-up Protocol Utilizing Rapid Molecular Diagnostic Testing
title_sort 1802. evaluation of clinical pharmacists use of a blood culture follow-up protocol utilizing rapid molecular diagnostic testing
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6254690/
http://dx.doi.org/10.1093/ofid/ofy210.1458
work_keys_str_mv AT kerriganalexandra 1802evaluationofclinicalpharmacistsuseofabloodculturefollowupprotocolutilizingrapidmoleculardiagnostictesting
AT percivalkelly 1802evaluationofclinicalpharmacistsuseofabloodculturefollowupprotocolutilizingrapidmoleculardiagnostictesting
AT brockjeff 1802evaluationofclinicalpharmacistsuseofabloodculturefollowupprotocolutilizingrapidmoleculardiagnostictesting